NSCLC Cell Adhesion to and Transmigration through Brain Endothelium in Brain Metastasis

Samah A. Jassam
Zaynah Maherally
Helen L. Fillmore
Geoffrey J. Pilkington
Brain Tumour Research Centre, University of
Portsmouth, UK
Corresponding Author:
Geoffrey J. Pilkington,

Approximately 33%of intracranial tumors are secondary metastases originating from primary non-CNS cancers. Indeed, 20%–40%of patients with systemic cancers develop secondary brain tumors1. Brain metastasis is the most important fatal complication of systemic cancer, especially in diagnoses of breast cancer2,3. There have been great advances in the diagnosis and treatment of breast cancer, with a 5-year survival rate >90% (when a diagnosis is made early). While many patients with early diagnoses will live their lifetimes without metastasis, >90%of the half million patients with metastasis will succumb to this cancer per year, with a majority due to brain metastasis3. Metastasis involves a series of multiple
steps, and determining which of these steps are optimal in terms of targeted therapies for metastatic seeding is not clear4–6. For example, could blocking breast cancer
circulating tumor cells (CTCs) from binding to brain endothelial cells prevent the seeding of breast cancer in the brain, and could this be used as preventive therapy 7?The highest incidence of brain metastasis is seen in lung cancer patients (40%–50%), followed by breast cancer (20%–30%) and melanoma (5%–10%) patients8. In particular, the brain is known to be a key target for metastasis from the lung; 20%–40% of patients with non-smallcell lung cancer (NSCLC) have been reported to develop secondary brain tumors 9. Brain metastasis is of considerableclinical importance and correlates with poor prognosis.

Leave a Reply

Your email address will not be published. Required fields are marked *